If you want additional support during the process, you can explore our Weight Loss Boost supplement for metabolic support during weight loss
If you hit a plateau lasting several weeks at your current dose, your provider may recommend moving to the next level
(November 1999)
This condition, mainly caused by bacterial infections, oxidative stress, high-fat diet, exposure to alcohol or chronic allergens, and dysbiosis, appear to be highly connected with the development and/or progression of several metabolic and autoimmune systemic diseases, including obesity, non-alcoholic fatty liver disease (NAFLD), neurodegeneration, cardiovascular disease, inflammatory bowel disease, and type 1 diabetes mellitus (T1D)
Those cases may support an upgrade to E11.42 (polyneuropathy) or E11.43 (autonomic neuropathy), which may improve clinical specificity and reduce payer queries